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Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine
approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei
rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a
failure to protect against P. berghei, despite successful antibody induction against leading merozoite
antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed
efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or
NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was
not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Dsmac P. berghei
parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms
responsible for protection, or failure of protection, against P. berghei merozoites could guide the
development of an efficacious vaccine against P. falciparum.
D
espite the deployment of effective control and prevention strategies, Plasmodium falciparum malaria
remains a huge burden on global public health1. The development of a highly effective vaccine is still
necessary if ambitions for local elimination, and ultimate eradication, are to be realized. Promising results
in Phase IIb field trials with the leading candidate vaccine, RTS,S, raised hopes that this formulation may be an
effective contributor to malaria control public health measures2. However, more recent results in a Phase III trial,
especially in the target infant age group, have revealed relatively low levels of efficacy against clinical and severe
malaria3. Further work is vital in order to develop and establish a highly effective vaccine for use in the field4, and
the continuing deaths of nearly amillion children each year demonstrates the urgency with which this work needs
to take place1.
Numerous vaccine strategies have been proposed to tackle the complex lifecycle of the Plasmodium parasite.
Leading vaccines in clinical development primarily target the sporozoite and/or liver-stages of parasite develop-
ment5. However significant efforts have also been made to develop vaccines against the pathogenic blood-stage
infection6 – especially given this is the lifecycle stage of the parasite against which natural immunity is acquired
following repeated exposure7. Numerous blood-stage candidate vaccines have now been tested in over 40 Phase I/
II clinical trials6, but the field has faced much disappointment without a single formulation demonstrating
significant efficacy in the primary endpoint of a Phase IIa/b clinical trial. A substantial number of these vaccines
have targeted the leadingmerozoite antigens merozoite surface protein 1 (MSP1) and apical membrane antigen 1
(AMA1)8–11 – targets historically identified as associated with naturally-acquired immunity, and important for
the invasion process of new host red blood cells12,13.Most recently, a Phase IIb field trial of a protein vaccine, based
on the 42 kDa C-terminus of MSP1 (MSP142) in Kenya showed no efficacy9, but encouragingly strain-specific
efficacy was reported in the secondary analysis of a mono-valent vaccine based on the 3D7 allele of AMA1 tested
in Malian children10. Intriguingly, a previous Phase IIa controlled human malaria infection (CHMI) study of the
same vaccine in US adult volunteers showed no significant efficacy against challenge with the homologous 3D7
parasite clone14. It remains to be established whether future AMA1 vaccine candidates can overcome the
significant hurdles surrounding the problems of antigen polymorphism15.
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Vaccine research relies heavily on animal models to screen putat-
ive candidates, and the MSP1 and AMA1 targets have been prev-
iously validated in this manner as protective determinants of
vaccine-induced antibodies12,13. In particular, rodent malaria species
and some chimeric rodent/human malaria models have been widely
used to assess the merits of various vaccine delivery platforms and
candidate antigens16,17. The P. yoelii and P. chabaudi rodent malaria
species have both been commonly utilized to demonstrate protection
against blood-stage parasitemia by vaccines targeting the ortholo-
gousMSP1 andAMA1 antigens18–22. In the case ofMSP1, the 19 kDa
C-terminus of MSP1 (MSP119) has been found to be critical for the
induction of antibody-mediated protection23, whilst the neighbour-
ing 33 kDa region (MSP133) appears important for T cell help24,25.
Numerous subunit vaccines therefore rely on the use of the entire C-
terminal MSP142 region24, whilst some protein-in-adjuvant vaccines
can induce antibody-mediated protection when based on MSP119
alone20.
P. berghei represents a third rodent malaria species that has
been widely used for the assessment of pre-erythrocytic26,27 and
transmission-blocking28,29 subunit vaccine efficacy. However, despite
the widespread use of this model, a search of the literature revealed
only three English-language publications that have demonstrated
protection against blood-stage P. berghei by subunit vaccination30–
32. Subunit vaccines that are reported to have been successful in
protecting against blood-stage P. berghei strain NK65 in BALB/c
mice include P. berghei NK65 merozoite surface protein 9
(PbMSP9) N-terminus recombinant protein formulated in alum30;
a recombinant Salmonella vaccine encoding regions of blocks 3 and 4
of PbMSP1 ANKA strain31; and a recombinant protein against
PbMSP119 in alum32. The recombinant Salmonella vaccine addition-
ally demonstrated limited protection against P. berghei NK65 strain
in outbred CD1 mice31. A further paper published in Chinese
describes induction of partial protection against blood-stage P. ber-
ghei following immunization with recombinant PbAMA1 in
Freund’s adjuvant33. Despite the limited number of studies dem-
onstrating protection against blood-stage P. berghei malaria follow-
ing subunit vaccination, it is this species of rodent malaria that forms
the basis of currently available chimeric parasites, designed for test-
ing and optimizing P. falciparum vaccines against the blood-stage in
mice34,35.
It is possible that additional laboratories have tested blood-stage
subunit vaccines targeting P. berghei but publication bias has resulted
in a lack of published descriptions of failures to achieve protection.
However, more recently, two publications have reported failed pro-
tection by subunit vaccines targeting PbMSP1 and PbAMA136,37. A
head-to-head comparison of blood-stage vaccine efficacy against P.
berghei ANKA or P. yoelii 17XL using baculoviral-based vaccines
(BBV) targeting P. berghei or P. yoeliiMSP119 and AMA1 found that
BBV vaccines could induce complete or partial protection against P.
yoelii but not against P. berghei in BALB/c mice36. In the second
study, DNA vaccines expressing PbMSP142 were tested with and
without fusion to a putative molecular adjuvant (complement protein
C3d) in BALB/c mice37. In this study both adjuvanted and control
vaccines induced anti-PbMSP142 antibody responses, but neither of
the two vaccines protected against P. berghei blood-stage challenge.
In agreement with these studies, here we report on similar dif-
ficulties relating to the induction of protective immunity against P.
berghei using viral vectored vaccines, as well as recombinant protein-
in-adjuvant, targeting well-studied merozoite antigens which have
previously been successful in protecting against P. yoelii and P.
chabaudi18–21,24,38,39. Protection was not achieved against either the
ANKA or NK65 P. berghei strains, nor in a range of inbred mouse
strains following active subunit immunization. Similarly, neither
active immunization with vaccines against PfMSP1 nor passive
transfer of anti-PfMSP119 IgG from rabbits afforded protection in
mice against a P. berghei parasite line chimeric for P. falciparum
MSP119. An improved understanding of protective immune
mechanisms against P. berghei merozoites is therefore still needed,
and could help to guide the development of an effective vaccine
against P. falciparum.
Results
P. berghei MSP119 protein vaccine production and immuno-
genicity. Recombinant PyMSP119 protein-in-adjuvant vaccines are
known to provide high levels of protection against P. yoelii blood-
stage parasite challenge20,39 and protection against P. chabaudi can be
similarly induced using vaccines encoding the orthologous antigen
(PcMSP119)21. In order to assess whether similar vaccines could
protect against P. berghei, we generated a comparable protein
subunit vaccine. Recombinant PbMSP119 protein from the ANKA
strain was produced and purified from E. coli as a soluble GST-fusion
protein as described in Methods.
To test the immunogenicity of GST-PbMSP119 protein, BALB/c
mice were immunized using a regime that has been shown to induce
extremely high levels of protective efficacy against P. yoelii pRBC
challenge following PyMSP119 immunization20. Five doses of 20 mg
GST-PbMSP119 protein were administered using CFA (at week 0),
IFA (weeks 3, 6, 8) and PBS (week 9). Sera were collected at regular
intervals (weeks 5, 9, 11) and assessed by ELISA. The total IgG titer
against GST-PbMSP119 increased significantly over time, as further
doses of protein were administered (Figure 1a). As the ELISA assay
was unable to distinguish between anti-GST and anti-PbMSP119
responses, P. berghei immunofluorescence assays (IFA) were also
performed using sera collected from mice two weeks following the
final immunization of five doses of GST-PbMSP119 protein (week
11). The use of these immunized sera in IFA against P. bergheiANKA
thin-blood smears confirmed the presence of IgG capable of binding
to native PbMSP119 protein (Figure 1b).
P. berghei blood-stage viral vector vaccine production and immu-
nogenicity. Similar to protein vaccines, AdHu5-MVA viral vector
prime-boost regimes targeting PyMSP142 have been demonstrated
to induce protection against blood-stage P. yoelii challenge18.
Recombinant AdHu5 and MVA viruses encoding PbMSP142 from
the ANKA strain were produced in order to determine the
immunogenicity and protective efficacy of viral vectors against P.
berghei. Mice were immunized with AdHu5 expressing PbMSP142
and eight weeks later were boosted with MVA expressing the same
antigen. This regime induced PbMSP119-specific total IgG, and titers
significantly increased following the MVA boost (Figure 2a).
Although this ELISA used the same GST-PbMSP119 protein as
above, the entirety of the measured response following viral vector
immunization will be directed to the PbMSP119 moiety. Moreover,
similar to the protein vaccine, endpoint titers here as determined by
ELISAwere also high, thus confirming the strong immunogenicity of
the viral subunit vaccine delivery platform.
The viral vectored vaccine platform is suited to the purposes of
antigen screening40, and thus whilst generating vectors encoding
PbMSP142, similar recombinant AdHu5 and MVA vaccines were
also generated encoding the PbAMA1 and PbMSP9 antigens, for
which protection data have previously been reported in the P. berghei
model30,33. These vectors were also used to immunize groups of
BALB/c mice in a similar manner to those encoding PbMSP142.
Recombinant PbAMA1 or PbMSP9 antigens were not available to
test the induction of antibodies by ELISA, and therefore the induc-
tion of antibodies capable of recognizing native parasite antigen by
vaccination was instead confirmed by IFA. Sera from AdHu5-MVA
immunized BALB/c mice were assessed for binding to P. berghei
ANKA mature schizonts (Figure 2b), which were the homologous
parasite for PbMSP142 and PbAMA1, but heterologous for PbMSP9
(where the antigen sequence was based on the NK65 strain of P.
berghei).However, these data demonstrated that the vaccines against
www.nature.com/scientificreports
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all three antigens were immunogenic, and confirmed that IgG anti-
bodies capable of binding to native antigen in schizonts were pro-
duced following AdHu5-MVA immunization with PbAMA1 and
PbMSP9, but not following immunization with vectors expressing
a control antigen (OVA).
Protective efficacy of MSP1 vaccines against blood-stage P.
berghei parasites. Mice can be sterilely protected against blood-
stage P. yoelii challenge using a schedule of five immunizations of
PyMSP119 (His6-tagged protein produced in Saccharomyces
cerevisiae in Freund’s adjuvant20). In order to determine if similar
Figure 1 | Immunogenicity of GST-PbMSP119 immunization. BALB/c mice (n5 5) were immunized with five doses of 20 mg GST-PbMSP119 protein.
Doses were administered at week 0 s.c. in CFA, at week 3 s.c. in IFA, at weeks 6 and 8 i.p. in IFA, and at week 9 i.p. in PBS. (a) Total IgG responses against
recombinant GST-PbMSP119 protein were measured by ELISA in the serum of mice taken at weeks 5, 9 and 11. Median and range of the titers are shown.
The dashed line indicates the lower limit of detection. ** P , 0.01 by Friedman test with Dunn’s correction for comparison of all time-points. (b) P.
berghei ANKA schizonts were fixed with 4% formaldehyde and permeabilized with 0.1%NP40. Pooled sera from week 11 in (A) were tested at a dilution
of 15100. Naı¨ve pre-immunization serumwas used as a negative control. Bound antibodies were detected using goat anti-mouse IgG conjugated to Alexa
Fluor 488. Images show left to right the visible schizonts, followed by fluorescence (green) and DAPI staining (blue).
Figure 2 | Immunogenicity of AdHu5-MVA viral vector vaccines. (a) BALB/c mice (n5 5) were immunized i.d. with 13 1010 vp AdHu5 and boosted
eight weeks later i.d. with 13 107 pfu MVA expressing PbMSP142. Total IgG responses against recombinant GST-PbMSP119 protein were measured by
ELISA in the serum of mice taken at weeks 2, 8 and 10. Median and range of the titers are shown. The dashed line indicates the lower limit of detection.
* P, 0.05 by Friedman test with Dunn’s correction for comparison of all time-points. (b) P. berghei ANKA schizonts were fixed with 4% formaldehyde
and permeabilized with 0.1% NP40. Sera from mice immunized with 13 1010 vp AdHu5 and boosted with 13 107 pfu MVA expressing the indicated
antigens were used at a dilution of 15100. Bound antibodies were detected using goat anti-mouse IgG conjugated to Alexa Fluor 488. Images show
fluorescence (green) and DAPI staining (blue).
www.nature.com/scientificreports
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protection could be seen in the P. berghei model, mice were
immunized as above with either the GST-PbMSP119 protein
vaccine or a previously described PyMSP119 vaccine, termed
PyMSP119-IMX108 41. Subsequently, in a head-to-head experiment,
the mice were challenged with homologous strain blood-stage
parasites (P. berghei ANKA or P. yoelii YM respectively). However,
only PyMSP119 immunized mice were protected against a corres-
ponding blood-stage Plasmodium infection. Sterile protection
against P. yoelii was seen in all immunized mice (Figure 3a) whilst
PbMSP119 immunized mice showed no protection against P. berghei
either at the onset of patent infection (Figure 3b), or throughout the
course of the infection (Figure 3c,d). As before (Figure 1a), the
PbMSP119 immunized mice achieved high antibody titres to their
respective MSP119 protein, and the PyMSP119 immunized mice also
developed high endpoint titers prior to challenge [ELISA assay
against GST-PyMSP119 protein showed a median endpoint of 1.3
3 106 with a range of 0.423 106–1.93 106]. Thus despite induction
of IgG antibodies against both MSP119 antigens by the protein–in-
adjuvant vaccines, protective efficacy was only achieved against P.
yoelii.
Viral vectored vaccines are capable of inducing antibodies against
encoded transgenes, but induce qualitatively different types of res-
ponses as well as cellular immunity18,39. We have previously reported
that significant protection against P. yoelii pRBC challenge can be
achieved using a schedule of just two immunizations in an AdHu5-
MVA PyMSP142 heterologous prime-boost regime, without a need
for additional adjuvant18. Protection following pRBC challenge is
dependent on the induction of high-titer anti-PyMSP119 antibody
responses18,20. In order to determine if similar protection could be
seen with P. berghei MSP142, BALB/c mice were immunized with
AdHu5-MVA vaccines as described earlier. As expected, both
AdHu5-MVA PbMSP142 and AdHu5-MVA PyMSP142 immunized
mice achieved high antibody titres to their respective MSP119
proteins (data not shown), however only AdHu5-MVA PyMSP142
immunized mice were protected against a homologous blood-stage
Plasmodium infection. Protection against P. yoelii was seen in
AdHu5-MVA PyMSP142 immunized mice (Figure 4a), with delayed
onset parasitemia and 83% survival – comparable to previously pub-
lished data for the same regime using slightly higher viral vaccine
doses18. In contrast, AdHu5-MVA PbMSP142 immunized mice
showed no protection against P. berghei ANKA infection
(Figure 4b,c), identical to the results obtained with protein-in-adjuv-
ant immunized animals (Figure 3c,d).
Protective efficacy of AMA1 and MSP9 vaccines against blood-
stage P. berghei parasites. Despite the lack of efficacy with vaccines
encoding the C-terminal regions of PbMSP1, there have been reports
that immunization against PbAMA1 and PbMSP9 can elicit
Figure 3 | Efficacy of P. yoelii and P. berghei MSP119 protein immunization. BALB/c mice (n 5 5/group) were immunized with five doses of 20 mg
GST-PbMSP119 protein (Pb) or a recombinant PyMSP119 protein fused to IMX108 (Py) as described in Figure 1. Ten days following the final
immunization Pb vaccinated mice and naı¨ve non-immunized controls were challenged i.v. with 53 102 P. berghei ANKA pRBC. Similarly Py vaccinated
mice and naı¨ve non-immunized controls were challenged i.v. with 1 3 104 P. yoelii YM pRBC, followed by daily monitoring for parasitemia. (a) Py
vaccinated mice were sterilely protected (monitored out to day 21). Day 4 parasitemias for individual control and vaccinated mice with medians are
shown. (b) Day 5 parasitemias for individual Pb vaccinated mice and controls are shown with medians, as well as time courses of parasitemia for
individual (c) control and (d) Pb vaccinatedmice. { indicates thatmice were culled, and the number culled from the total number in the group is shown in
brackets.
www.nature.com/scientificreports
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protection against P. berghei at the blood-stage30,33. We therefore
assessed the efficacy of the viral vector vaccines targeting PbAMA1
and PbMSP9 in BALB/c mice. Mice were immunized with AdHu5
expressing PbAMA1, PbMSP9 or no malaria antigen and then
boosted with MVA expressing the same antigen. Two weeks later
mice were challenged with 5 3 102 P. berghei ANKA pRBC and
monitored daily. Similar to PbMSP142, no significant efficacy was
observed with either of these vaccines compared to control
immunized mice (Figure 5). By day 7 post-challenge, 8/8 PbAMA1
immunized mice were culled (Figure 5a), compared to 3/8 PbMSP9
(Figure 5b) immunized and 1/8 control (Figure 5c) immunizedmice.
This was not due to a difference in parasitemia between groups, but
rather reflected symptomatic illness which was pre-defined as the
humane endpoint. All remaining mice reached this point by day 13
post-infection. Overall, these data show an absence of efficacy of both
the PbMSP9 and PbAMA1 antigens, delivered by AdHu5-MVA,
against blood-stage P. berghei ANKA infection.
Published studies demonstrating protection at the blood-stage
against P. berghei were all noted to have employed an NK65 strain
challenge30–32. Biological differences between P. berghei strains have
been observed, such as differences in virulence, sensitivity to drugs,
and preference for invasion of normocytes or reticulocytes42,43.
The AdHu5-MVA vaccines encoding PbMSP142, PbAMA1 and
PbAMA1, or a co-administered mixture of all three, were therefore
additionally tested against challenge with P. berghei NK65 pRBC.
Also, given the PbMSP9 immunogen was originally based on the
NK65 strain sequence, this experiment allowed for a homologous
parasite challenge, in comparison to heterologous challenge as in the
previous experiment. However, as seen with P. berghei ANKA, no
protective efficacy was observed in any of the vaccinated mice
(Supplemental Figure 1).
Protective efficacy ofMSP1 and AMA1 vaccines against P. berghei
sporozoite challenge. In previous studies with the AdHu5-MVA
vectors encoding PyMSP142, we reported improved efficacy and
survival outcome against P. yoelii strain YM sporozoite challenge
in comparison to pRBC challenge. In these studies, vaccinated
mice showed complete survival against a challenge dose of both 50
and 250 sporozoites24.
In the case of PbMSP142, BALB/cmice, immunized as before, were
challenged with 500 sporozoites 14 days following the MVA boost.
However, similar to the pRBC challenge studies, no efficacy was
observed in vaccinees as compared to non-immunized controls
(Figure 6a). To confirm that this lack of efficacy was not specific to
the BALB/c strain, we also tested this regime in C3H and C57BL/6
mice. Despite achieving higher anti-PbMSP119 antibody titers in
C3H mice (Figure 6b) we still observed no efficacy following spor-
ozoite challenge (Figure 6a).
In addition to its well-known blood-stage role, AMA1 is also
known to be expressed on sporozoites44, and DNA and viral vectored
vaccines encoding P. falciparum AMA1 have shown some potential
pre-erythrocytic efficacy in humans against controlled infection deliv-
ered by mosquito bites8,45. We therefore additionally tested AdHu5-
MVA PbAMA1 vaccines against sporozoite challenge in C57BL/6
Figure 4 | Efficacy of AdHu5-MVA PbMSP142 and PyMSP142 immunization. BALB/c mice (n 5 6/group) were immunized i.d. with 1 3 1010 vp
AdHu5 and boosted eight weeks later i.d. with 13 107 pfuMVA expressing (a) PyMSP142 or (b) PbMSP142. Twoweeks following the final immunization
vaccinated mice and non-immunized controls were challenged with (a) 13 104 P. yoelii YM or (b,c) 53 102 P. berghei ANKA pRBC and monitored for
parasitemia. Lines represent individual mice. { indicates that mice were culled and the number culled from the total number in the group is shown in
brackets.
www.nature.com/scientificreports
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(Figure 6c) as well as outbred CD1 mice (Figure 6d). Following
challenge with 2000 sporozoites, there was no significant protection
observed in either of the mouse strains, although there was a single
PbAMA1 vaccinated animal on the outbred CD1 background that
did not become parasitemic, indicating that on rare occasions
PbAMA1 may be able to impart some protective efficacy in this
model. However, given the extremely low level of efficacy afforded,
the potential mechanism(s) of protection were not further explored.
Figure 5 | Efficacy of AdHu5-MVAPbAMA1 and PbMSP9 immunization against P. berghei ANKApRBC infection. BALB/cmice (n5 8/group) were
immunized i.d. with 1 3 1010 vp AdHu5 and boosted thirteen weeks later with 1 3 107 pfu MVA encoding either PbAMA1, PbMSP9 or no malaria
antigen (Control). Two weeks post-boost mice were challenged with 5 3 102 P. berghei ANKA pRBC and monitored for parasitemia. Lines represent
individual mice. { indicates that mice were culled and the number culled from the total number in the group is shown in brackets.
Figure 6 | Efficacy of AdHu5-MVA PbMSP142 and PbAMA1 immunization against P. berghei ANKA sporozoite infection. (a) Mice (n5 6-8/group)
were immunized i.d. with 13 1010 vp AdHu5 and boosted eight weeks later i.d. with 13 107 pfu MVA expressing PbMSP142. Two weeks following the
final immunization vaccinated mice and naı¨ve non-immunized controls were challenged with 5 3 102 P. berghei ANKA sporozoites. Each mouse was
monitored for the development of blood-stage infection. Parasitemia for individual vaccinated (V) and non-immunized control (C) mice and medians
are shown at day 7 following challenge of three different inbredmouse strains (BALB/c, C57BL/6 and C3H). (b) Total IgG responses against recombinant
GST-PbMSP-119 protein were measured by ELISA in the serum of mice taken pre-challenge at week 2 post-boost immunization. Individual titers and
medians are shown. (c) C57BL/6 and (d) CD1mice (n5 6–8/group) were immunized i.m. with 83 109 vp AdHu5 and boosted eight weeks later i.m. with
1 3 107 pfu MVA expressing PbAMA1. Two weeks following the final immunization vaccinated mice and non-malaria antigen vector-immunized
controls were challengedwith 2000 P. bergheiANKA sporozoites.Median and individual time to 1%parasitemia is shown.OneCD1mouse showed sterile
protection and did not develop patent blood-stage infection.
www.nature.com/scientificreports
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Protective efficacy of P. falciparum MSP1 vaccines against a
chimeric P. berghei parasite. Novel chimeric parasite lines have
also been developed to enable functional assessments of immune
responses to P. falciparum antigens in small mammals16. The
chimeric P. berghei parasite model Pb-PfM19 was developed to
enable the testing of vaccines targeting the P. falciparum MSP119
antigen in mice34. Antibody-mediated protection against Pb-
PfM19 in mice has been demonstrated following passive transfer
of monoclonal or polyclonal antibody into mice or following
infection with Pb-PfM19 and drug-cure34,46,47. We have previously
reported the preclinical development of human and simian
adenoviral as well as MVA vectored vaccines encoding PfMSP1-
based transgenes termed PfM115 and PfM128 48. These vectors
induced anti-PfMSP119 IgG responses in mice and rabbits that
showed functional growth inhibitory activity (GIA) against P.
falciparum parasites in vitro18,40,48,49. A chimpanzee adenovirus 63
(ChAd63) and MVA encoding PfM128 have also been shown to
immunogenic for PfMSP119 antibody induction in Phase I/IIa
clinical trials8,50. In a parallel series of experiments to those
reported above using wild-type P. berghei parasites, we also tested
the protective efficacy of PfMSP1-based vaccines following active
immunization of mice. In agreement with data using the PbMSP1-
based vaccines, no protective efficacy or effect of the vaccine on
blood-stage parasite growth was conferred following AdHu5-MVA
immunization with the PfM115 immunogen, following challenge
with 104 pRBCs of the chimeric parasite (Table 1). We observed
the same results in both BALB/c and C57BL/6 mice when the
experiment was repeated using a lower challenge dose of 500
pRBCs as employed in another published study47. We also tested a
recombinant PfMSP119-based protein vaccine, previously reported41,
administered in Freund’s adjuvant and similarly observed no efficacy
in BALB/c mice. Overall, these data confirmed that active
immunization of inbred mouse strains with subunit vaccines
encoding the PfMSP119 antigen failed to elicit efficacy against a
pRBC challenge with the chimeric Pb-PfM19 parasite.
Protection against the chimeric parasite Pb-PfM19 by active sub-
unit PfMSP1 vaccine immunization was not possible in our hands
and has not been reported elsewhere. However, sterile protection of
BALB/c mice following i.v. transfer of 900 mg purified total IgG from
PfMSP142-immunized rabbits has been reported in one study47, and
also in a second study using 1.5 mg purified total IgG from
PfMSP119-immunized rabbits and an alternative but highly similar
chimeric parasite35. We thus also investigated here whether passive
transfer could protect against challenge with the Pb-PfM19 parasite.
Total IgG was purified from the serum of New Zealand white rabbits
that had previously been immunized with an AdHu5-MVA or
ChAd63-MVA regime and vectors encoding the PfM128 antigen.
These rabbits had raised antibody responses against the 3D7/
MAD20/ETSR allele of PfMSP119 that were comparable to those
reported in our previous studies (Supplemental Figure 2A) and
homologous to the PfMSP119 strain D10 sequence in the chimeric
parasite34. Rabbits were primed i.m. with 5 3 1010 vp ChAd63 or
AdHu5 expressing PfM128 on day 0 and boosted i.m. with 1 3
108 pfu MVA-PfM128 on day 56. Serum was harvested two weeks
later on day 70. Day 0 pre-immune IgG from the same rabbits and
from a control viral vector immunized rabbit were also purified.
0.5mg IgG was transferred i.v. to BALB/c mice on days 21, 0 and
11, and on day 0mice were challenged with 53 102 PbPfM19 pRBC
by i.v. injection. However, no significant differences in parasitaemia
were observed between any groups following challenge (Supple-
mental Figure 2B).
The role of FccRIIb (CD32b) in antibody-mediated protection
against P. berghei. The data so far have demonstrated an inability
of vaccines targeting three different merozoite antigens to protect
against blood-stage P. berghei infection. Data from natural infection
studies have suggested antibody Fc-mediated mechanisms are
important in protection against blood-stage P. berghei. This is
supported by the findings that mice lacking the common c
signalling chain, required for activatory signalling through Fc-
gamma receptors (FccR), have increased susceptibility to blood-
stage P. berghei XAT infection51. Additional support is observed as
human antibodies against PfMSP119 were able to protect against the
chimeric Pb-PfM19 parasite only in mice transgenic for human
FccRI (CD64)46. The inhibitory effect of IgG1 binding to the
inhibitory Fc receptor (CD32b/FccRIIb) may in fact act to prevent
activatory signals induced by IgG2a through other FcRs52,53. Given
viral vectored vaccines are known to induce both IgG1 and
IgG2a18,48,54, FccRIIb knockout mice (CD32b2/2) were therefore
used to investigate whether removing the inhibitory signals
induced through FccRIIb allowed protection against blood-stage P.
berghei infection to be observed following subunit vaccination.
CD32b2/2mice on a C57BL/6 background were immunized with
AdHu5-MVA vectors expressing either PbMSP142 or no antigen
(vector control). As before, anti-PbMSP119 IgG responses were
induced by immunization (Figure 7a). Two weeks post-boost, mice
were challenged with P. berghei ANKA pRBC and monitored for
parasitemia. No significant differences in parasitemia were observed
in the PbMSP142 immunized mice (Figure 7b) in comparison to
control immunized (Figure 7c) or naı¨ve non-immunized mice
(Figure 7d). The lack of the FccRIIb also did not appear to influence
the kinetics of the infection in naı¨ve mice, with no significant differ-
ences observed in parasitemia between naı¨ve non-immunized
CD32b2/2 (Figure 7d) and naı¨ve non-immunized wild-type
C57BL/6 mice (Figure 7e). This result suggests that the lack of
Table 1 | Chimeric parasite challenge experiments. Protein or viral vectored vaccines were administered as shown. Regime lists dose, route
and day (d) of immunizations. Survival outcome is reported for the Pb-PfM19 chimeric parasite, andwild-type Pb-PbM19 control. n.d.5 not
done. N/A 5 not applicable
Vaccine Regime Challenge Antigen Mouse strain
Pb-PfM19
survival
Pb-PbM19
survival
PfMSP119-IMX108 33 40 mg s.c. d0, d14, d28 d42 PfMSP119 BALB/c 0/6 n.d.
CFA/IFA/IFA 104 pRBC i.v.
AdHu5-MVA 53 1010 vp i.d. d0 d70 PfM115 BALB/c 0/6 0/6
53 107 pfu i.d. d56 104 pRBC i.v.
Naı¨ve N/A 104 pRBC i.v. N/A BALB/c 0/3 1 0/6 0/6
AdHu5-MVA 53 1010 vp i.d. d0 d70 PfM115 BALB/c 0/6 n.d.
53 107 pfu i.d. d56 53 102 pRBC i.v.
AdHu5-MVA 53 1010 vp i.d. d0 d70 PfM115 C57BL/6 0/6 n.d.
53 107 pfu i.d. d56 53 102 pRBC i.v.
Naı¨ve N/A 53 102 pRBC i.v. N/A BALB/c 0/6 n.d.
Naı¨ve N/A 53 102 pRBC i.v. N/A C57BL/6 0/6 n.d.
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vaccine efficacy in wild-type mice was not due to inhibitory signal-
ling through FccRIIb preventing activatory IgG2a-mediated signals.
The role of sequestration in antibody-mediated protection against
P. bergheimerozoites.We also tested a final hypothesis as to whether
sequestration of P. berghei parasites was affecting the efficacy of the
anti-merozoite vaccines. We considered that sequestration of infected
erythrocytes might reduce the period of exposure of merozoites to
antibody. Studies have shown sequestration of P. berghei pRBC in
bone marrow, thereby bringing parasites in close proximity to
immature RBCs in particular55. Such attributes of the parasite could
potentially favour rapid RBC invasion by newly released merozoites,
leaving minimal time in which antibodies could interfere with this
process. To test this, we made use of a recently described P. berghei
parasite line that cannot sequester, due to ablation of CD36 binding
as a result of deletion of the smac gene56. Studies with this parasite
have indeed suggested that pRBC sequestration may confer
advantages to parasite growth in addition to avoidance of splenic
removal56. BALB/c mice were immunized with the AdHu5-MVA
vaccines encoding PbMSP142, PbAMA1 or PbMSP9, or a co-
administered mixture of all three, and subsequently challenged with
Dsmac pRBCs. However, similar to all the other studies, no vaccine
efficacy was apparent in this case. Parasitemias were comparable
between the vaccinees and controls (Supplemental Figure 3), and
all mice were culled on day 10 post challenge.
Discussion
Here we report on the ability of subunit vaccines targeting theMSP1,
AMA1 and MSP9 antigens to protect against blood-stage P. berghei
Figure 7 | Efficacy of AdHu5-MVA PbMSP142 in CD32b2/2 mice. CD32b2/2 mice were immunized i.d. with 1 3 1010 vp AdHu5 and boosted eight
weeks later i.d. with 13 107 pfuMVA encoding either no antigen (Control) or PbMSP142. (a)Ondays 14, 54 (pre-boost) and 70 (2weeks post-boost) sera
were collected and PbMSP119-specific total IgG measured by ELISA. Dots represent individual mice and bars show median endpoint titre. * P 5 0.02
between d54 and d70 by Wilcoxon matched pairs signed rank test. The dashed line indicates the lower limit of detection. Two weeks post-boost (b)
PbMSP142 immunized CD32b
2/2 mice and (c) control immunized mice were challenged with 5 3 102 P. berghei ANKA pRBC and monitored for
parasitemia. Groups of (d) non-immunized (naı¨ve) CD32b2/2 and (e) wild-type C57BL/6 mice were also challenged. Lines represent individual mice of
5–7mice/group (females solid lines andmales dashed lines). { indicates that mice were culled. The number culled that day from the total number of mice
in the group is shown in brackets.
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parasites. Active immunization with subunit vaccines targeting these
merozoite antigens has previously been reported to protect against
blood-stage P. berghei infection in only four studies30–33. Following
active immunization of BALB/c mice here with AdHu5-MVA vec-
tors expressing these three P. bergheimerozoite antigens, antibodies
capable of binding to native parasite antigen were observed, indi-
cating that all three antigen-delivery regimes were immunogenic.
In addition, vector immunization against PbMSP142 induced
PbMSP119-specific IgG that reached high endpoint titers in an
ELISA assay. However, despite induction of these responses, no pro-
tection was afforded against P. berghei ANKA pRBC challenge. We
observed similar results in a variety of inbred mouse strains, includ-
ingC3Hmice that developed the highest antibody titers. If protection
is antibody-mediated in this mouse model, we cannot exclude the
possibility that titers induced by viral vector immunization were too
low to protect, or that the fine specificity of the antibody response
was qualitatively non-protective. Also, it is possible the PbMSP1
vaccines targeted an incorrect region of the molecule; given res-
ponses against the PbMSP1 N-terminal region may be important
(as reported for a recombinant Salmonella-based vaccine31).
However, this is not the case in the P. yoelii and P. chabaudimodels
and is therefore unlikely. Delivery of the orthologous PyMSP142 or
PcAMA1 antigens respectively by AdHu5-MVA is protective against
blood-stage challenge in mice (shown here and in previous
reports18,19). Similarly immunization with MSP119 protein in
Freund’s adjuvant (a regime capable of inducing extremely high titer
responses) was shown here to afford sterilizing immunity against P.
yoelii (in agreement with an earlier report of the same regime20), but
no efficacy against either wild-type P. berghei or the chimeric Pb-
PfM19 parasite.
Initial pRBC challenge experiments were performed using P.
berghei ANKA. However in the published examples of protection
against wild-type blood-stage P. berghei by subunit vaccination, the
challenge strain was P. berghei NK65 rather than ANKA30–32. P. ber-
gheiNK65 infection results in a greater number of ‘latent merozoites’
than ANKA, meaning merozoites are in the blood for longer (and
thus potentially more accessible to antibody) before invading a new
RBC57. NK65 is also known to i) have a greater predilection to invade
immature RBC (reticulocytes); ii) be more likely to multiply infect
the same cell; and iii) produce more ring forms early in infection43,
leading to a less synchronous infection than the ANKA strain.
Challenge experiments were therefore repeated using P. berghei
NK65 but, despite these differences, no efficacy was seen. It cannot
be excluded that the failure to protect against P. bergheiNK65may be
due to differences in homology between the vaccine antigens and
NK65 challenge strain (in the case of PbMSP142 and PbAMA1).
However, assessment of sequence data from NK65 and ANKA P.
berghei parasite lines found no differences in PbAMA1 and only one
SNP in PbMSP1 (CJJ and BMF-F, unpublished observations), and in
the case of PbMSP9 (based on the NK65 sequence) antibodies raised
by AdHu5-MVA vaccination were capable of recognizing P. berghei
ANKA schizonts in the IFA. Moreover, no protection was also
observed against sporozoite challenge (bar in the case of one animal
immunized with PbAMA1), despite the possibility of viral vectored
immunization leading to the development of CD81 T cells capable of
targeting P. berghei liver-stage forms. Such liver-stage protection has
been reported using the same vectors in the PyMSP142 model24.
Overall these data are in agreement with more recently published
studies showing a lack of anti-PbMSP142 and -PbAMA1 vaccine
efficacy in mice36,37, and add to the growing body of evidence that
P. berghei may possess mechanisms that can circumvent such res-
ponses.
Studies with a non-lethal/attenuated strain P. berghei XAT
(derived from P. berghei NK65 58) have shown that protection
requires IFN-c and IgG2a59. Similarly, FcR were shown to be essen-
tial in mediating blood-stage protection against Pb XAT following
infection of FcR common c-chain knockout mice51. Protection was
also reported against the Pb-PfM19 chimeric parasite using a human
IgG1 mAb against PfMSP119, but only in transgenic mice expressing
the human FccRI (CD64)46, but not for an isotype switched human
IgA mAb against the same epitope in human FcaRI (CD89) trans-
genic mice60. In agreement with this, a similar experiment with the
‘non-cytophilic’ mouse IgG1 isotype failed to show protection in
wild-type mice (although ‘cytophilic’ IgG2a was not tested)61. We
therefore tested here whether vaccine-induced protection against the
merozoite antigens could be improved in mice lacking the inhibitory
FccRIIb (CD32b). This knockout would be more likely to enhance
the action of mouse IgG1 (due to the greater inhibition of this isotype
and low activatory-to-inhibitory (A:I) ratio62) but could still also
enhance the action of vaccine-induced IgG2a and IgG2b – known
to be induced by AdHu5-MVA vaccination18,48,54. Immunization of
CD32b2/2 mice might also be expected to enhance immune res-
ponses to the vaccine due to removal of the regulatory/inhibitory
FccR signalling at the time of immunization. This has been reported
in studies for antibodies63,64 as well as tumor-specific CD81 T cells65.
Wild-type and CD32b2/2 mice were not directly compared in this
study, and in future it will be important to establish the impact of
CD32b absence on vaccine immunogenicity. However, IgG res-
ponses were clearly primed and boosted against PbMSP119 in the
knockout mice but, despite the absence of possible inhibitory
FccRIIb signalling, no vaccine efficacy was observed. No difference
was also observed between naı¨ve wild-type and knockout mice, again
in contrast to the P. chabaudi infection model that observed reduced
parasitemia in CD32b2/2 mice66.
In contrast to subunit vaccines against the merozoite, whole para-
site immunization protocols ofmice can afford significant protection
against subsequent parasite challenge. Such protocols may involve
drug-cure, immunization with killed parasites in adjuvant or expo-
sure to attenuated/non-lethal infection. Interpretation of such stud-
ies is complicated by the significant variability observed with each
different protocol and each unique inbred mouse and parasite strain
combination67. Nonetheless, following such ‘immunization’ proto-
cols mice are typically protected against homologous challenge,
whilst outcome of heterologous challenge varies significantly.
However, early studies clearly document reduced levels of efficacy
afforded by exposure to replicating P. berghei parasites as compared
to the other rodent malaria species68. In 1977 Playfair et al. also
documented differences in the ease with which protection could be
achieved between rodent malaria species following administration of
a killed blood-stage vaccine. Whilst lysed and fixed P. yoelii pRBC
induced homologous protection that was at least partly antibody-
mediated, similar experiments with P. berghei pRBC led to little or no
protection69. Although formalin-killed blood-stage parasites are able
to protect against P. berghei this protection is incomplete and mice
develop parasitemia levels of,10%. The mechanism of this protec-
tion appears to be at least partly antibody-mediated as delay to para-
sitemia occurred following the transfer of immune sera to non-
immunised mice70. Protective immunity in mice against blood-stage
challenge could also be induced by self-limiting infections with
growth-attenuated P. berghei ANKA parasites mutants lacking plas-
mepsin 4 71. Following challenge, the trophozoite/schizont-infected
RBCs were trapped in the spleen resulting in rapid and efficient
removal of parasites from the circulation. These observations indi-
cate that the protective blood-stage immunity induced in this case
was mediated against pRBC rather than merozoite invasion.
Proposed reasons for the difficulty in protecting against P. berghei
include sequestration of the parasite, immune suppression or eva-
sion, and antigenic variation. P. berghei pRBC sequester in a similar
way to P. falciparum, through adherence to the host receptor CD36
and such sequestration appears to be beneficial for parasite growth56.
However, anti-merozoite vaccine efficacy was not improved
here when tested against the Dsmac parasite line, suggesting this
www.nature.com/scientificreports
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sequestration phenotype is unlikely to be helping P. berghei parasites
circumvent such immune responses. Another possible contributor to
the difficulty in protecting against blood-stageP. bergheimight be the
suppression of the immune system during parasite infection. Blood-
stage P. berghei can rapidly suppress MHC class I and class II pre-
sentation of both malarial and other antigens by dendritic cells
within 4 days of infection72. Such a phenomenon may prevent the
essential development of de novo protective immune responses or the
boosting of vaccine-induced antibodies. However, the vaccines tested
here were ineffective against the first 4 days of parasite growth – a
period in which pre-existing vaccine-induced responses are probably
critical, and which probably precedes the development of either
parasite-induced immunosuppression or substantial infection-
induced adaptive immune responses.
Protection against a chimeric P. berghei line expressing P. falci-
parum MSP119 was also assessed here. Similar to other reported
studies using baculoviral-based vaccines36, or PfMSP119 protein in
Freund’s adjuvant80, we again failed to protect against this parasite in
two strains of mice following active subunit vaccine immunization.
Passive transfer of IgG from PfMSP119-immunized rabbits or a
human mAb has been demonstrated to protect against challenge
with blood-stage Pb-PfM19 parasites46,47. However in our hands
polyclonal purified IgG, from PfMSP1 immunized rabbits, did not
protect against Pb-PfM19. It remains wholly possible that the anti-
body titers here were too low to protect, or that the antibodies were of
incorrect fine specificity. Protection of mice (made semi-immune to
this parasite line by drug-cure) from homologous pRBC challenge
correlated with PfMSP119-specific inhibitory antibodies, but not
with titers of total PfMSP-119 IgG34. However, these PfMSP1 immu-
nogens have been previously shown to be recognized by conforma-
tional inhibitory anti-PfMSP119mAbs and to raise IgG in rabbits that
show functional activity in vitro48. Intriguingly, in both reported
results to date where passive immunization was successful46,47, ster-
ilizing immunity was observed. Partial efficacy or blood-stage con-
trol has not been reported. Successful outcomemay therefore rely on
an immediate clearancemechanism of the challenge inoculum rather
than reduced rates of RBC invasion, though this requires further
investigation. The Pb-PfM19 parasite used here also lacks the first
four aa of PfMSP119 and instead expresses the first 4 aa of
PbMSP11934, and this may affect the ability of IgG to inhibit
MSP142 processing. Although protection against this parasite by
transfer of PfMSP142-specific IgG has been observed47, the indepen-
dently developed chimeric parasite developed by Cao et al.35, pos-
sesses the full length PfMSP119 sequence and may be a more suitable
parasite line for future experiments.
Overall, these data suggest a failure of vaccines against commonly
studied merozoite antigens to protect against P. berghei blood-stage
infection, in contrast to many similar studies using P. yoelii and P.
chabaudi. Although qualitative differences in the immune responses
induced by the P. berghei vaccines tested here may explain the failure
to protect, this remains unlikely given the success of both viral vector
and protein/adjuvant vaccine platforms targeting the same antigens
from other rodent malaria species and in raising IgG that is func-
tional against P. falciparum in vitro. A fraction of parasite-derived
material containing unknown antigens was recently reported to be
protective in this model73, and thus vaccines targeting other blood-
stage proteins may yet prove to bemore effective. Despite supporting
data obtained using the P. yoelii and P. chabaudi models, protein/
adjuvant and viral vectored PfMSP1- and PfAMA1-based vaccines
have faced significant disappointment in Phase IIa/b clinical trials to-
date6,8. It may well be that the seemingly more stringent P. berghei
mouse model will prove to be a better predictor of P. falciparum
clinical vaccine efficacy. These observations have important implica-
tions for the development of chimeric parasite models used to test P.
falciparum vaccine candidates, and the interpretation of future stud-
ies demonstrating protection in one or other mouse model16. Further
studies remain warranted to establish whether or not P. falciparum
does indeed sharemechanisms with P. berghei that potentially enable
this rodent malaria to circumvent immune responses induced by
vaccines against merozoite antigens such as MSP1 and AMA1.
Methods
Viral vector vaccine generation. Recombinant human adenovirus serotype 5
(AdHu5) and modified vaccinia Ankara (MVA) viral vector vaccines expressing
candidate antigens were designed according to previously published methods18. All
vectors encoded the transgene of interest (listed below), with an N-terminal in-frame
signal sequence fromhuman tissue plasminogen activator (tPA). Adenoviral vaccines
were grown in HEK293 cells, purified by CsCl centrifugation74 and titered by UV
spectrophotometry to give units of viral particles (vp/mL)18, whilst MVA vaccines
were grown in chicken embryo fibroblasts (CEFs), purified by centrifugation through
a sucrose cushion75 and titered by fluorescence plaque assay using the GFP marker to
give plaque-forming units (pfu/mL)18.
PbMSP9. PbMSP9 NK65 strain (GenBank AY302245) commenced at amino acid
(aa) 23 (histidine) and was truncated at aa 392 (glutamic acid)30. In order to remove
potential sites of N-linked glycosylation, the serine residues at aa sites 96, 155, 171,
301 and 338 were substituted with alanine. An additional serine residue at aa site 284
was substituted with alanine to remove an active serine protease site and avoid
potential toxicity in vitro during virus propagation (ADD, SJD unpublished
observations). The transgene was synthesized by GeneArt GmbH (Regensburg,
Germany) and codon optimized for expression in mice.
PbAMA1. PbAMA1 ANKA strain (GenBank U45969) commenced at aa 21
(cysteine) and was truncated at aa 478 (glutamic acid). In order to remove potential
sites of N-linked glycosylation, serine residues at aa sites 160, 233, 251, 290, 407 and
412 were substituted with alanine, and asparagine at aa site 189 was substituted with
glutamine. The gene was synthesized as for PbMSP9.
PbMSP142. The 42 kDa C-terminus of P. bergheiMSP1 was amplified from genomic
DNA extracted from wild-type P. berghei ANKA strain (Pb-PbM19)34 using the
following oligonucleotide primers (see below for description of parasites and PCR
method): forward primer 59-TCC GAA AAT GCA CAA GAA AAA AAT A-39;
reverse primer 59-TCCCATAAAGCTGGAAGAGCTACAGAA-39. Primers were
designed to amplify DNA from aa site 1416 (serine) and finish prior to the GPI
anchor at aa site 1776 (glycine) (PlasmoDB: PBANKA_083100).
PfMSP1. Vaccines encoding the P. falciparum MSP1 inserts termed PfM115 and
PfM128 have been described previously48. Briefly, the PfM115 insert encodes a
115 kDa composite P. falciparumMSP1 antigen. From N- to C-terminus it includes
the conserved blocks of MSP1 sequence (blocks 1, 3, 5 and 12) from the 3D7 clone,
followed byWellcome strain block 16 (MSP133), linked by a glycine-proline linker to
3D7 clone blocks 16 and 17 (MSP142). PfM128 encodes a 128 kDa insert as described
above for PfM115, except the Wellcome strain MSP133 sequence was replaced with
the sequence encoding MSP142.
PyMSP142.AdHu5 andMVA vectors encoding MSP142 from P. yoelii YM have been
previously described18.
Ovalbumin and no malaria antigen controls. AdHu5 and MVA vectors encoding
hen ovalbumin (OVA) have been previously described39, as have AdHu5 lacking a
transgene amd MVA encoding only GFP38.
Protein vaccines.Generation of recombinant P. yoelii strain YMMSP119-glutathione
S-transferase (GST) fusion protein has been described previously18. Recombinant
PyMSP119 and PfMSP119 fused to IMX108 (mouse complement C4 binding protein,
C4bp)41 were kindly provided byDr F.Hill (Imaxio, France). Recombinant PbMSP119
was produced as a GST fusion protein using previously published methods18. To
generate the vector, PbMSP119 (aa methionine 1669 – glycine 1776) was amplified
from the PbMSP142 sequence described above by PCR and cloned into the expression
vector pGEX-2T (Amersham Biosciences, Bucks., UK).
Animals and immunization studies. All procedures were performed in accordance
with the terms of the UK Animals (Scientific Procedures) Act Project Licence and
were approved by the University of Oxford Animal Care and Ethical Review
Committee (PPL 30/2414). Six to eight week old female BALB/c (H-2d), C3H (H-2k),
C57BL/6 (H-2b) and CD1 (outbred) mice were obtained from Harlan, UK, and
housed in specific pathogen-free conditions. Unless otherwise stated, mice were
immunized intramuscularly (i.m.) with 1 3 1010 vp AdHu5 vaccines and then
boosted eight weeks later with 13 107 pfuMVA expressing the same antigen, as per a
previously established immunization regime18,24. Protein vaccines were administered
at doses of 20 mg at weeks 0 (subcutaneously, s.c.), 3 (s.c.), 6 (intraperitoneally, i.p.),
8 (i.p.) and 9 (i.p.). The adjuvant used for subcutaneous injection at week 0 was
complete Freund’s adjuvant (CFA) and at weeks 3, 6 and 8 was incomplete (IFA). At
week 9 protein was administered in PBS. This regime was based on a published
protocol20 shown to induce very high-titer antibody responses. Sera were collected
from tail vein bleeds as described in Results.
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Fcc receptor IIb (CD32b) deficient mice on a C57BL/6 background (CD32b2/2)63
were provided from the Queen’s Medical Centre, Nottingham, UK and bred at the
Wellcome Trust Centre for Human Genetics, Oxford, UK. Genotype was confirmed
using DNA extracted from tissue samples and the Expand High Fidelity PCR Kit
(Roche Diagnostics, UK) and previously described reaction conditions76, except the
primers were: 59-CTC GTG CTT TAC GGT ATC GCC-39 (Mutant); 59-AAA CTC
GAC CCC CCG TGG ATC-39 (Common); and 59-TTG ACT GTG GCC TTA AAC
GTG TAG-39 (Wild-type).
New Zealand white rabbits were used for all rabbit experiments. Vaccines were
shipped from Oxford and the immunization of rabbits and collection of sera was
performed by Agrobio, France. Rabbits were immunized i.m. on day 0 with 5 3
1010 vp AdHu5 or ChAd63 expressing PfM128 or no malaria insert (control) and
then boosted i.m. on day 56 with 1 3 108 pfu MVA expressing PfM128 or GFP
(control). Serum was collected pre-immunization on day 0 as well as two weeks post-
boost on day 70.
Rabbit IgG purification. Polyclonal rabbit IgG was purified from serum samples by
Protein G affinity chromatography using a buffer system (Immunopure, Pierce)
according to manufacturer’s instructions. IgG was quantified using a
spectrophotometer at 280 nm. The extinction coefficient for rabbit IgG is 1.44 (i.e.
1 mg/mL of rabbit IgG has an OD of 1.44 at 280 nm). The concentration of antibody
was therefore calculated as follows: Concentration of rabbit IgG (mg/mL) 5 (OD3
dilution factor)/1.44.
Immunogenicity assays. Mouse and rabbit total IgG ELISAs were performed
according to previously published methods48. Briefly, protein was coated onto ELISA
plates at a concentration of 2 mg/mL in PBS. Test sera were applied in duplicate wells
and serially diluted. The endpoint titers were taken as the x-axis intercept of the
dilution curve at an absorbance value 3 3 standard deviations greater than the
OD405 nm for naı¨ve mouse sera.
Immunofluorescence assays (IFA) were performed using methods based on those
described previously48. Briefly, blood from P. berghei infected mice was cultured in
vitro overnight to enable development of schizonts. Slides were prepared with a thin
smear of this blood. Slides were fixed with 4% formaldehyde and 0.1% NP40 for
15 min at room temperature (RT). Mouse sera were diluted 15100 in PBS and
incubated on slides for 45 min. Slides were washed with PBS and incubated with
Alexa Fluor 488 goat anti-mouse IgG for 30 min. Slides were washed in PBS, DAPI
was applied, and the slides were viewed under a fluorescence microscope.
Parasites. P. berghei NK65 (MR4 Number: MRA-268) was obtained through the
Malaria Research and Reference Reagent Resource Centre (MR4) and was deposited
by Prof. V. Nussenzweig, New York University, USA. P. berghei strain ANKA clone
234, strain NK65 or P. yoelii strain YM parasitized red blood cell (pRBC) challenges
were carried out as previously described18,77. Briefly, donor mice were infected by i.p.
injection of cryopreserved infected blood stocks, before passage into experimental
mice which were infected by intravenous (i.v.) injection with 500 (P. berghei) or
10,000 (P. yoelii) pRBCs unless otherwise stated. Parasitemia wasmonitored fromday
3 post-challenge by Giemsa-stained thin blood smear and was calculated as a
percentage of infected RBC. Mice were considered uninfected if no parasites were
observed in 50 fields of view. For P. berghei strain ANKA 234 sporozoite challenge
studies, infected Anopheles stephensi mosquitoes were prepared as previously
described78. Salivary glands were collected by dissection and placed in a tissue
homogenizer with RPMI 1640 (Sigma) to release the sporozoites, which were then
counted using a haemocytometer. Unless otherwise stated, mice were challenged i.v.
with 500 sporozoites andmonitored for blood-stage infection from day 5 as for pRBC
challenge. In some cases, a linear-regressionmodel was generated to predict time until
1% parasitemia as previously described79.
A chimeric parasite line known as Pb-PfM19 and a control parasite line, Pb-
PbM19, were kindly provided by Dr B. S. Crabb and Dr T. F. de Koning-Ward. These
chimeric parasite lines were generated using an allelic replacement approach, on a P.
berghei ANKA background34. Pb-PfM19 expresses P. falciparum strain D10 MSP119
(MAD20/ETSR allele) in place of wild-type PbMSP119, and Pb-PbM19 was generated
as a transfection control, replacing wild-type PbMSP119 with the identical wild-type
sequence. The identity of the two parasite lines was confirmed before the studies by
PCR. Infected blood at 5–10% parasitemia was harvested fromBALB/c donormice by
cardiac exsanguination into 10 mM EDTA. Blood was made up to 5 mL with PBS,
and white blood cells filtered out using a Plasmodipur filter (Euro-Diagnostica, The
Netherlands). Erythrocytes were washed in PBS before extraction of parasite DNA
using aQIAamp BloodMini Kit (Qiagen). Parasite identity was confirmed by Expand
High Fidelity PCR (Roche Diagnostics, UK) according to the manufacturer’s
instructions and using 4 mMMgCl2 and an annealing temperature of 52uC. Species-
specific primers were used for MSP119: PfMSP119 (59-ATG CGT AAA AAA ACA
ATG TCC AGA AAA T-39; 59-GTT AGA GGA ACT GCA GAA AAT ACC ATC
G-39) and PbMSP119 (59-CTG CAA ATG CTG GAT GTT TTA GAT A-39; 59-CAT
CAT AAT ATG CAT TAG GGG TTG G-39). Amplified DNA fragments were of the
expected fragment sizes (PbMSP1195 228 bp, PfMSP1195 271 bp) and identities for
their respective parasites (data not shown).
P. berghei ANKA parasites lacking the schizont membrane-associated cytoadher-
ence protein (SMAC) have previously been described (Dsmac; reference 56; mutant
1160cl7; RMgm ID: RMgm-661). Dsmac parasites exhibit reduced CD36-mediated
sequestration and reduced growth rates in wild-type mice.
Statistics.Data were analyzed using GraphPad Prism v5.03. Continuous outcomes in
two independent groups were compared using a Mann-Whitney U test, or using the
Wilcoxon matched pairs signed rank test for paired data. A Kruskal-Wallis test with
post-hoc Dunn’s analysis was used to compare responses between more than two
groups. A Friedman test was used for paired data when there were more than two
time-point observations. In all cases P# 0.05 was considered significant (* P# 0.05
and ** P # 0.01).
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